Picard Medical, Inc. - What You Need to Know

Thinking about investing in Picard Medical? It is exciting to get in on the ground floor, but let’s break down what this company actually does in plain English.

Here is your "friend-to-friend" guide to the Picard Medical deal.

1. What does this company do?

Picard Medical owns "SynCardia." They manufacture the only FDA-approved Total Artificial Heart (TAH) in the United States. It acts as a life-saving bridge for patients with end-stage heart failure while they wait for a transplant. Unlike partial pumps, the SynCardia TAH replaces both heart ventricles and all four valves. They are currently developing "Emperor," a next-generation, fully implantable system designed to improve patient mobility.

2. How do they make money?

They earn revenue by selling TAH units and leasing portable "drivers"—the consoles that power the heart.

Their business relies on a small group of major medical centers. They do not have long-term contracts, so hospitals order on a case-by-case basis. Hospitals can stop ordering at any time without penalty. If a key center switches to alternative technologies, Picard could lose a significant portion of its revenue overnight.

3. The "big picture" on their finances

Picard is in a difficult financial spot. They lost $22.7 million in the first nine months of 2025. Their auditors have issued a "going concern" warning, meaning they doubt the company can stay in business without raising more money.

To stay afloat, the company has issued debt. Lenders received the right to buy stock at $2.675 per share.

Crucial point: This offer is for the resale of 17 million shares by these lenders, not an offering by the company. Picard receives no cash from these sales. When lenders convert their debt into stock, the company issues more shares. This reduces your ownership percentage and can push the stock price down.

4. What are the main risks?

• Manufacturing Fragility: The TAH is a complex device handmade by a small team in Tucson, Arizona. Any issue at this single facility would halt production. They also lack backup suppliers for critical parts. If a supplier fails, Picard cannot fulfill orders.
• Financial Health: The "going concern" warning from their accountants signals that the company may struggle to pay its bills.
• Market Adoption: The TAH requires removing the patient's heart, which can cause hesitation among surgeons and families. Also, the current external driver is bulky and noisy, making it less attractive than quieter, less invasive alternatives.
• Regulatory Hurdles: The company faces strict FDA oversight. If they fail to secure approvals for the "Emperor" system, they cannot grow or improve their product line.

5. The "Bottom Line" for You

Picard is a high-risk, speculative investment. They are burning cash, relying on debt, and facing major manufacturing and competitive hurdles.

Before you decide, ask yourself these three questions:

1. Do I believe the "Emperor" system will be successful enough to turn this company around?
2. Am I comfortable with the risk that the company may need to raise more money, which could dilute the value of my shares?
3. Is this investment a small enough part of my portfolio that I can handle the volatility?

Don't feel pressured to rush in. Take your time to look at their latest SEC filings if you want to dig deeper into the numbers.

Disclaimer: I am an AI, not a financial advisor. These investments are volatile. Never invest money you cannot afford to lose, and always do your own research.